跳到正文
BioPharm International·· 18 天前AI 评分33

Aldevron与IDT推出PE Ultra先导编辑mRNA及6种ABE8e碱基编辑mRNA

Aldevron, IDT Launch Base and Prime Editing mRNAs for Gene Editing

AI 导读

Aldevron与Integrated DNA Technologies(均为Danaher旗下公司)于2026年11月4日推出研究级PE Ultra先导编辑mRNA和6种ABE8e碱基编辑mRNA,可在不产生双链断裂的情况下编辑DNA。

正文 · 原文

Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.

Aldevron and Integrated DNA Technologies (IDT), both Danaher companies, announced on November 4, 2026, the launch of research-grade messenger RNA (mRNA) products designed to simplify base and prime editing workflows.¹ The offering combines IDT's gene editing expertise with Aldevron's mRNA manufacturing. It expands on the companies' earlier Cas9 mRNA portfolio with tools for precise, programmable changes to genomic DNA without double-strand breaks.¹

Key facts

  • Companies: Aldevron and Integrated DNA Technologies (Danaher)
  • Prime editing: PE Ultra mRNAs plus chemically modified Alt-R pegRNAs
  • Base editing: 6 stocked ABE8e-based mRNA variants plus parallel screening kit
  • Design support: IDT bioinformatics tool for pegRNA design
  • Scales: 20 µg to 1 mg stocked; larger via custom order
  • Grade: research grade, research use only
  • Prior launch: S. pyogenes Cas9 mRNA (wild type and SpyFi), September 2026

"The challenge is not simply to make more editing tools available—it is to bring the right capabilities together around the problems researchers need to solve," said Christopher Vakulskas, PhD, senior director of applied science and molecular design at IDT, in a company press release.¹

What products are being launched?

For prime editing, the companies developed PE Ultra mRNAs, which feature an engineered prime editor. They pair these with chemically modified Alt-R prime editing guide RNAs (pegRNAs) that contain a proprietary modification pattern designed to enhance editing performance.¹ IDT also released a bioinformatics tool for pegRNA design intended to help researchers narrow candidates for testing.¹

For base editing, the companies now offer 6 stocked ABE8e-based mRNA variants spanning different protospacer adjacent motif (PAM) compatibilities and fidelity profiles, plus a screening kit for evaluating all 6 editors in parallel.¹ IDT has also released Alt-R CRISPR-Cas9 sgRNA XT, a clustered regularly interspaced short palindromic repeats (CRISPR)–Cas9 single guide RNA (sgRNA) product, for use in base editing and Cas9-mediated workflows using mRNA.¹ The stocked base and prime editing mRNA products are available at scales of 20 µg to 1 mg, with larger scales available from Aldevron through custom orders.¹

What challenges are the products designed to address?

Base editing enables a single targeted nucleotide change, while prime editing supports precise substitutions, insertions, and deletions, both without creating a double-strand break in the target DNA.¹ Prime editing was first described in 2019 as a "search-and-replace" approach. It uses a catalytically impaired Cas9 fused to an engineered reverse transcriptase, programmed with a prime editing guide RNA.²

According to the companies, prime editing often struggles to reach efficient editing rates across targets and cell types.¹ Base editing can be limited by PAM restrictions and variable editor activity. Those limits can reduce the number of targetable sites and make it difficult to identify the optimal editor for a given application.¹

How does the launch build on earlier products?

The launch follows the companies' September 2026 introduction of research-grade Streptococcus pyogenes Cas9 mRNA in wild-type and SpyFi high-fidelity formats. That mRNA is compatible with electroporation, cationic lipids, and lipid nanoparticles.¹,³ At that time, the companies said base and prime editors would follow later in the year. They also described a path for customers moving from early research to current good manufacturing practice (CGMP) manufacturing.³ The companies said that initial offering provided mRNA-based options that are particularly well suited for in vivo applications.¹

Why does it matter for gene editing development?

Regulators are also adapting to precision editing approaches. In October 2026, FDA issued draft guidance outlining how sponsors can submit a single biologics license application for individualized genome editing products tailored to each patient's genetic variant.⁴ The draft would allow new patient-specific variants to be added to an approved BLA using in vitro data rather than new clinical trials.⁴

What are the limitations?

The newly launched products are research grade and intended for research use only, not for diagnostic or therapeutic procedures.¹ The announcement contained no performance data and directed users to product documentation. The companies also did not disclose timelines for CGMP versions of the base and prime editing mRNAs.

References

  1. Aldevron. Aldevron and Integrated DNA Technologies launch new mRNA solutions to simplify base and prime editing. Press release. Published November 4, 2026. Accessed November 4, 2026. https://www.aldevron.com/about-us/news/mrna-cas9-prime-and-base-editing-expansion
  2. Anzalone AV, Randolph PB, Davis JR, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576(7785):149-157. doi:10.1038/s41586-019-1711-4
  3. Aldevron. Integrated DNA Technologies and Aldevron launch new Cas9 mRNA solutions. Press release. Published September 16, 2026. Accessed November 4, 2026. https://www.aldevron.com/about-us/news/idt-aldevron-launch-new-cas9-mrna-solutions
  4. US Department of Health and Human Services. FDA and CMS announce new steps to advance gene therapies and expand access for patients with rare diseases. Press release. Published October 27, 2026. Accessed November 4, 2026. https://www.hhs.gov/press-room/fda-cms-advance-gene-therapies-rare-diseases-patient-access.html

Related to this article

FDA headquarters at White Oak Campus in Silver Spring, Maryland, USA - January 13, 2020. The United States Food and Drug Administration (FDA) is a federal agency. | Image credit: © JHVEPhoto - © JHVEPhoto - stock.adobe.com

November 3rd, 2026

Final FDA guidance replaces 2011 potency testing advice, asking CGT makers to build potency assurance from IND filing through postmarket monitoring.

Read more

Q&A: What AI Reveals That Scientists Could Not See Before

November 4th, 2026

Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.

Read more

Various of international money coin and banknote with blurred hourglass in the background. Time investment with currency exchange concept. Focus on dollar banknote. | Image credit: © zephyr_p - © zephyr_p - stock.adobe.com

November 3rd, 2026

Shilpa CDMO's $50 million plan adds 10 kL of SPPS reactor capacity in Raichur, India, with its first commercial peptide line opening in December 2026.

Read more

Drug Digest: Reshoring Manufacturing and Securing Cold-Chain Supply for Biopharma

October 30th, 2026

Industry experts discuss how reshoring, fill/finish capacity, and cold chain technology are shaping a more resilient biopharma supply chain.

Read more

3D Rendering of Antibody Drug Conjugate Molecules - ADC - with cytotoxic payload | Image credit: © Alpha Tauri 3D - © Alpha Tauri 3D - stock.adobe.com

October 30th, 2026

Lonza's Visp expansion adds 3 multiproduct suites at up to 1200 L plus 500-L single-use capacity to scale commercial ADC production from 2028.

Read more

white pill capsule isolated on white background | Image credit: © F16-ISO100 - © F16-ISO100 - stock.adobe.com

November 4th, 2026

Biora will test oral adalimumab via its BioJet capsule vs injection in healthy volunteers, with dosing from December 2026 and data in early 2027.

Read more

A disposable syringe is filled with a clear liquid and lies on a metal table. Disposable syringe with three glass vials of medicines. 3d render. | Image credit: © Alexandr - © Alexandr - stock.adobe.com

November 3rd, 2026

Teva will commercialize etanercept-ykro (Eticovo) and infliximab-abda, adding 2 TNF inhibitor biosimilars to US options for inflammatory diseases.

Read more

Stainless steel pilot-scale bioreactor with a sight glass, tubing, and valves next to a control cabinet with a touchscreen and peristaltic pumps. | Image Credit: © Grispb - stock.adobe.com

November 3rd, 2026

The deal adds five US sites and about 1,100 employees, more than doubling Lonza’s US network and filling a gap in US bioconjugation capacity the company flagged weeks earlier.

Read more

来源:BioPharm International · biopharminternational.com